摘要
目的:探讨阿托伐他汀钙联合沙库巴曲缬沙坦钠对慢性心力衰竭(CHF)患者心功能、心肌酶谱指标、甲状腺激素水平等的影响。方法:采集2018年7月至2020年3月登封市中医院CHF患者106例当作研究对象,依据纳入顺序单双号分组,每组53例。常规干预基础上,单一用药组予以阿托伐他汀钙,联合用药组给予阿托伐他汀钙联合沙库巴曲缬沙坦钠。比较两组疗效、治疗前与治疗6个月后心功能[左室舒张期内径(LVEDD)、左室射血分数(LVEF)、左室收缩末期内径(LVESD)]、血清细胞因子[可溶性ST2(sST2)、胎盘生长因子(PLGF)、半乳糖凝集素-3(galectin-3)]水平、甲状腺激素水平[游离三碘甲状腺素(FT3)、三碘甲状腺原氨酸(TT3)]、不良反应发生率。结果:联合用药组治疗总有效率92.45%高于单一用药组77.36%(P<0.05);治疗6个月后,联合用药组LVEF、FT3、TT3水平明显较单一用药组高,LVEDD、LVESD、血清sST2、PLGF、galectin-3水平明显较单一用药组低(P<0.05);两组间不良反应发生率比较差异无统计学意义(P>0.05)。结论:阿托伐他汀钙联合沙库巴曲缬沙坦钠治疗CHF患者疗效显著,能改善心功能,调控血清sST2、PLGF、galectin-3水平,并能调节甲状腺激素水平,安全性高。
Objective:To investigate the effects of atorvastatin calcium combined with shakubactrivalsartan sodium on cardiac function,myocardial enzyme profiles and thyroid hormone levels in patients with chronic heart failure(CHF).Methods:A total of 106 CHF patients in Dengfeng Hospital of Traditional Chinese Medicine from July 2018 to March 2020 were collected as the research subjects,and were divided into odd-even groups according to the inclusion order,with 53 patients in each group.On the basis of conventional intervention,the monotherapy group was given atorvastatin calcium,while the combination group was given shakubactrivalsartan sodium based on monotherapy.Therapeutic effect,cardiac function[left ventricular diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD)],serum cytokines[soluble ST2(sST2),placental growth factor(PLGF),galectin-3],Thyroid hormone level[free triiodothyroxine(FT3),triiodothyroxine(TT3)],incidence of adverse reactions were compared between the two groups before and after 6 months of treatment.Results:The total effective rate of combined drug group was 92.45%higher than that of single drug group 77.36%(P<0.05).After 6 months of treatment,the levels of LVEF,FT3 and TT3 in the combined drug group were significantly higher than those in the single drug group,and the levels of LVEDD,LVESD,serum sST2,PLGF and galectin-3 were significantly lower than those in the single drug group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Atorvastatin calcium combined with Shaqubatrivalsartan sodium has significant efficacy in the treatment of CHF patients,which can improve cardiac function,regulate serum sST2,PLGF,galectin-3 levels,and regulate thyroid hormone levels,with high safety.
作者
梁彩云
张跃刚
LIANG Caiyun;ZHANG Yuegang(Dengfeng Hospital of Traditional Chinese Medicine,Zhengzhou Henan 452470,China)
出处
《药品评价》
CAS
2021年第17期1079-1082,共4页
Drug Evaluation
